MARVELD2

Across TCGA pan-cancer cohorts, MARVELD2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MARVELD2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MARVELD2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MARVELD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where MARVELD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.715	0.944	.001	24	view →
CCRCC	OS	Quartile	All	1.000	0.706	.019	12	view →
PDAC	DFS	Quartile	All	0.684	0.922	.004	10	view →
LSCC	DFS	Quartile	III,IV	1.000	0.374	.019	7	view →
LUAD	OS	Tertile	All	0.884	0.634	.010	6	view →
GBM	OS	Tertile	All	0.306	0.967	.036	4	view →
UCEC	OS	Tertile	All	1.000	0.904	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MARVELD2–HNSC (OS)

Open the HNSC breakdown →